Differential Ubiquitination as an Effective Strategy Employed by the Blood-Brain Barrier for Prevention of Bacterial Transcytosis

被引:4
|
作者
Bhutda, Smita [1 ]
Ghosh, Sourav [1 ]
Sinha, Akash Raj [1 ]
Santra, Shweta [1 ]
Hiray, Aishwarya [1 ]
Banerjee, Anirban [1 ]
机构
[1] Indian Inst Technol, Dept Biosci & Bioengn, Bacterial Pathogenesis Lab, Mumbai, Maharashtra, India
关键词
Streptococcus pneumoniae; K48-ubiquitination; K63-ubiquitination; autophagy; proteasomal degradation; blood-brain barrier; proteasome; ubiquitin topology; ubiquitination; SELECTIVE AUTOPHAGY; MAMMALIAN-CELLS; RECOGNITION; PROMOTES; MENINGITIS; PROTEINS; INVASION; RECEPTOR; YEAST;
D O I
10.1128/JB.00456-21
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The protective mechanisms of blood-brain barrier (BBB) prohibiting entry of pathogens into central nervous system (CNS) are critical for maintenance of brain homeostasis. These include various intracellular defense mechanisms that are vital to block transcytosis of neurotropic pathogens into the CNS. However, mechanistic details of coordination between these defense pathways remain unexplored. In this study, we established that BBB-driven ubiquitination acts as a major intracellular defense mechanism for clearance of Streptococcus pneumoniae, a critical neurotropic pathogen, during transit through BBB. Our findings suggest that the BBB employs differential ubiquitination with either K48- or K63-ubiquitin (Ub) chain topologies as an effective strategy to target S. pneumoniae toward diverse killing pathways. While K63-Ub decoration triggers autophagic killing, K48-Ub directs S. pneumoniae exclusively toward proteasomes. Timelapse fluorescence imaging involving proteasomal marker LMP2 revealed that in the BBB, the majority of the ubiquitinated S. pneumoniae was cleared by proteasome. Fittingly, inhibition of proteasome and autophagy pathway led to accumulation of K48Ub- and K63-Ub-marked S. pneumoniae, respectively, and triggered significant increases in intracellular S. pneumoniae burden. Moreover, genetic impairment of either K48- or K63-Ub chain formation demonstrated that although both chain types are key in disposal of intracellular S. pneumoniae, K48-Ub chains and subsequent proteasomal degradation have more pronounced contributions to intracellular S. pneumoniae killing in the BBB. Collectively, these observations, for the first time, illustrated a pivotal role of differential ubiquitination deployed by BBB in orchestrating a symphony of intracellular defense mechanisms for interception and degradation of S. pneumoniae, blocking its entry into the brain, which could be exploited to prevent bacterial CNS infections. IMPORTANCE The blood-brain barrier (BBB) represents a unique cellular barrier that provides structural integrity and protection to the CNS from pathogen invasion. Recently, ubiquitination, which is key for cellular homeostasis, was shown to be involved in pathogen clearance. In this study, we deciphered that the BBB deploys differential ubiquitination as an effective strategy to prevent S. pneumoniae trafficking into the brain. The different ubiquitin chain topologies formed on S. pneumoniae dictated the selection of downstream degradative pathways, namely, autophagy and proteasomes, among which the contribution of the proteasomal system in S. pneumoniae killing is more pronounced. Overall our study revealed how the BBB deploys differential ubiquitination as a strategy for synchronization of various intracellular defense pathways, which work in tandem to ensure the brain's identity as an immunologically privileged site.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Blood-brain barrier - Size matters at the blood-brain barrier
    Green, E
    NATURE REVIEWS NEUROSCIENCE, 2003, 4 (07) : 525 - 525
  • [22] Protection of the Blood-Brain Barrier as a Therapeutic Strategy for Brain Damage
    Michinaga, Shotaro
    Koyama, Yutaka
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2017, 40 (05) : 569 - 575
  • [23] Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cell
    Descamps, L
    Dehouck, MP
    Torpier, G
    Cecchelli, R
    BIOLOGY AND PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER: TRANSPORT, CELLULAR INTERACTIONS, AND BRAIN PATHOLOGIES, 1996, 46 : 51 - 54
  • [24] Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells
    Descamps, L
    Dehouck, MP
    Torpier, G
    Cecchelli, R
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 270 (04): : H1149 - H1158
  • [25] Strategy of Escherichia coli for crossing the blood-brain barrier
    Kim, KS
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 : S220 - S224
  • [26] Quantification of kinetic rate constants for transcytosis of polymeric nanoparticle through blood-brain barrier
    Khan, Aminul Islam
    Lu, Qian
    Du, Dan
    Lin, Yuehe
    Dutta, Prashanta
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2018, 1862 (12): : 2779 - 2787
  • [27] Tumor necrosis factor-α increases lactoferrin transcytosis through the blood-brain barrier
    Fillebeen, C
    Dehouck, B
    Benaïssa, M
    Dhennin-Duthille, I
    Cecchelli, R
    Pierce, A
    JOURNAL OF NEUROCHEMISTRY, 1999, 73 (06) : 2491 - 2500
  • [28] Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor
    Friden, PM
    Olson, TS
    Obar, R
    Walus, LR
    Putney, SD
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 278 (03): : 1491 - 1498
  • [29] Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier
    Pflanzner, Thorsten
    Petsch, Benjamin
    Andre-Dohmen, Bettina
    Mueller-Schiffmann, Andreas
    Tschickardt, Sabrina
    Weggen, Sascha
    Stitz, Lothar
    Korth, Carsten
    Pietrzik, Claus U.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 (04): : 628 - 632
  • [30] Low nanogel stiffness favors nanogel transcytosis across an in vitro blood-brain barrier
    Ribovski, Lais
    de Jong, Edwin
    Mergel, Olga
    Zu, Guangyue
    Keskin, Damla
    van Rijn, Patrick
    Zuhorn, Inge S.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2021, 34